Aminocaproic Acid
FDA-approved product (tablet, oral), marketed as Amicar, Aminocaproic, Aminocaproic Acid and 1 more.
- Registered studies
- 36
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Amino acids
- FDA pharmacologic class
- Antifibrinolytic Agent FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Aminocaproic Acid, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA17.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli8.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis15.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
36registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Aminocaproic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
NCT00958581 · start 2008-12
Registered record
- Registry ID
- NCT00958581
- Conditions
- Scoliosis
- Interventions
- Tranexamic Acid; Normal Saline; Epsilon aminocaproic acid
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2012-09
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionScoliosisInterventionTranexamic Acid; Normal Saline; Epsilon aminocaproic acidPhasePhase 4Registry statusCompletedEfficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
NCT02655653 · start 2008-10
Registered record
- Registry ID
- NCT02655653
- Conditions
- Bleeding
- Interventions
- Epsilon-aminocaproic acid administered; Tranexamic Acid administered
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2015-10
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBleedingInterventionEpsilon-aminocaproic acid administered; Tranexamic Acid administeredPhasePhase 3Registry statusCompletedEffects of Aprotinin During Cardiac Surgery/Long Term Death Rates
NCT00617955 · start 2007-09
Registered record
- Registry ID
- NCT00617955
- Conditions
- Cardiac Surgery
- Interventions
- Aprotinin; Amicar
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2009-06
- Enrolment
- 462
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac SurgeryInterventionAprotinin; AmicarPhaseNot recordedRegistry statusCompletedBradykinin Receptor Antagonism During Cardiopulmonary Bypass
NCT00223704 · start 2006-05
Registered record
- Registry ID
- NCT00223704
- Conditions
- Cardiopulmonary Bypass; Inflammation; Fibrinolysis; Surgery
- Interventions
- HOE 140; Aminocaproic Acid; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2012-06
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiopulmonary Bypass; Inflammation; Fibrinolysis; SurgeryInterventionHOE 140; Aminocaproic Acid; PlaceboPhasePhase 2 / Phase 3Registry statusCompletedPlatelet Function And Aggregometry In Patients With Aortic Valve Stenosis
NCT00156520 · start 2005-03
Registered record
- Registry ID
- NCT00156520
- Conditions
- Hemorrhage
- Interventions
- aprotonin; epsilon aminocaproic acid
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2005-09
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHemorrhageInterventionaprotonin; epsilon aminocaproic acidPhasePhase 4Registry statusCompletedEpsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
NCT00320619 · start 2000-09
Registered record
- Registry ID
- NCT00320619
- Conditions
- Scoliosis; Kyphosis; Lordosis; Spondylitis; Spinal Stenosis
- Interventions
- Epsilon-Aminocaproic Acid (EACA); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2000-09
- Completion
- 2006-02
- Enrolment
- 182
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionScoliosis; Kyphosis; Lordosis; Spondylitis +1 moreInterventionEpsilon-Aminocaproic Acid (EACA); PlaceboPhaseNot applicableRegistry statusCompleted